



## Anti-migraine Agents – Other, CGRP Antagonists, 5-HT<sub>1F</sub> receptor agonist Utilization Management Criteria

<b>Therapeutic Class:</b>	Anti-migraine Agents – Other, CGRP Antagonists, 5-HT <sub>1F</sub> receptor agonist
<b>Non-Preferred Agents:</b>	Aimovig (erenumab-aooe), Emgality (galcanezumab-gnlm) 100 mg syringe, Reyvow (Lasmiditan), Vyepti (eptinezumab-jjmr), Zavzpret (zavegepant)
<b>Preferred Agents:</b>	Ajovy (fremanezumab-vfrm), Emgality (galcanezumab-gnlm) 120 mg pen/syringe, Nurtec ODT (rimegepant), Qulipta (atogepant), Ubrelvy (ubrogepant)
<b>Implementation Date:</b>	1/1/2026
<b>Prepared For:</b>	CT
<b>PDL Status:</b>	Non-preferred
<b>Purpose:</b>	<p>Migraine is a prevalent episodic or chronic disorder characterized by phases of severe headache, nausea, and sensory sensitivity. Managing chronic migraine requires a focus on prophylactic therapy, avoidance of triggers, and limitation of acute medications to prevent medication-overuse headaches. However, even with preventive therapy, migraines may still occur, making acute treatments—such as non-steroidal anti-inflammatory drugs (NSAIDs), triptans, gepants, and lasmiditan—essential for controlling breakthrough attacks and alleviating symptoms when prevention alone is insufficient.</p> <p>For acute migraine treatment, table 1 therapies include calcitonin gene-related peptide (CGRP) receptor antagonists (rimegepant, ubrogepant, and zavegepant) and the selective 5-HT<sub>1F</sub> receptor agonist lasmiditan. These agents are approved for adults with migraine with or without aura. Rimegepant is also approved for preventive treatment of episodic migraine.</p> <p>Erenumab, fremanezumab, galcanezumab, and eptinezumab are injectable monoclonal antibodies given by subcutaneous or intravenous injection (eptinezumab only). Atogepant is an oral agent and CGRP receptor antagonist. These agents are indicated for the preventative treatment of migraines in adults with the exception of fremanezumab which is indicated for the treatment of migraines in adults and pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. Galcanezumab is also indicated for the treatment of episodic cluster headache in adults.</p> <p>In a 2024 position statement for the prevention of migraine, the American Headache Society positioned CGRP-targeting agents as first-line options, placing CGRP monoclonal antibodies and gepants (atogepant, rimegepant) alongside traditional therapies and removing the requirement for patients to try older treatments before accessing these newer agents.</p>

**Table 1. Anti-migraine Agents - Other**

Generic Name	Brand Name	Approved Indications	Route of Administration	Generic Availability
Atogepant	Qulipta®	preventive treatment of migraine	PO	N
Eptinezumab-jjmr	Vyepti®	preventive treatment of migraine	IV	N
Erenumab-aooe	Aimovig®	preventive treatment of migraine	SC	N
Fremanezumab-vfrm	Ajovy®	preventive treatment of migraine	SC	N
Galcanezumab-gnlm	Emgality®	preventive treatment of migraine, treatment of episodic cluster headache	SC	N
Lasmiditan	Reyvow®	acute treatment of migraine with or without aura	PO	N
Rimegepant	Nurtec® ODT	acute treatment of migraine with or without aura, preventive treatment of migraine	SL, PO	N
Ubrogepant	Ubrelvy®	acute treatment of migraine with or without aura	PO	N
Zavegepant	Zavzpret™	acute treatment of migraine with or without aura	Nasal	N

Abbreviations: IV, intravenous; PO, oral; SC, subcutaneous; SL, sublingual

**All authorizations must be prescribed in accordance with FDA approved labeling. Use of samples to initiate therapy does not meet step therapy and/or continuation of therapy prior authorization requirements. Prior therapies will be verified through pharmacy claims and/or submitted chart notes**

**General Approval Criteria:**

- Requested quantity in accordance with FDA approved product labelling
- For specific formulation requests
  - **For brand requests when a therapeutically equivalent generic is preferred:** Provider must provide a documented medical reason the preferred generic formulation cannot be used
  - **For generic requests when a therapeutically equivalent brand is preferred:** Provider must provide a documented medical reason the preferred brand formulation cannot be used
  - **For non-preferred dosage or formulation requests:** Provider must provide a documented medical reason the preferred dosage or formulation cannot be used

**Initial Therapy – All the following must be met:**

**For the Preventative Treatment of Migraine (Aimovig, Vyepti)**

- Documentation of diagnosis of chronic or episodic migraine headaches with 4 or more migraine days per month
- Trial and failure of **ONE** preferred anti-migraine agent in this class (Ajovy, Emgality, Nurtec, Qulipta) (defined as a 30 day trial) indicated for the preventative treatment of migraine **OR** documented adverse reaction/adverse event or contraindication to Ajovy, Emgality, Nurtec and Qulipta



### For the Acute Treatment of Migraine (Zavzpret, Reyvow)

- Documentation of diagnosis of migraine headaches
- Trial and failure of **ONE** preferred anti-migraine agent in this class (Ubrelvy, Nurtec) (defined as a 30 day trial) indicated for the acute treatment of migraine **OR** documented adverse reaction/adverse event or contraindication to Ubrelvy and Nurtec
- Provider attests to advising patient not to drive or operate machinery until at least 8 hours after taking each dose of Reyvow (requirement for Reyvow only)

### For the Treatment of Episodic Cluster Headache (Emgality 100 mg)

- Documentation of diagnosis of episodic cluster headache defined as 2 cluster headache attacks occurring in periods lasting from 7 days to one year, separated by pain-free periods lasting at least 3 months
- Patient has previously failed **ONE** standard prophylactic agent or has contraindications to standard prophylactic therapy

### Non-preferred Age Limitations

- Aimovig, Emgality, Reyvow, Vyepti, Zavzpret: 18 years and older

### Claim Exceeds Maximum Dosing Limitations for Non-preferred Agents

Drug	Daily Dosing Limitation
Aimovig 70 mg autoinjector	1 pen per 28 days
Aimovig 140 mg autoinjector	1 pen per 28 days
Emgality 100 mg syringe	3 syringes per 28 days (1 carton)
Vyepti 100 mg	3 vials per 84 days
Zavzpret 10 mg	6 units (1 carton) per 22 days

**Initial PA length: 1 year**

**Exclusion Criteria:** Clinical criteria not met

**Continuation Therapy:** Documented compliance on current therapy regimen **AND** Documented continued clinical benefit (i.e. reduction in migraine/headache days) **AND**

- For specific formulation requests
  - **For brand requests when a therapeutically equivalent generic is preferred:** Provider must provide a documented medical reason the preferred generic formulation cannot be used
  - **For generic requests when a therapeutically equivalent brand is preferred:** Provider must provide a documented medical reason the preferred brand formulation cannot be used
  - **For non-preferred dosage or formulation requests:** Provider must provide a documented medical reason the preferred dosage or formulation cannot be used

**Continuation Length: 1 year**

## References:

1. Drugs@FDA: FDA Approved Drug Products. Accessed September 2025. <https://www.accessdata.fda.gov/scripts/cder/daf/>
2. DailyMed: National Library of Medicine. Accessed September 2025. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>
3. Facts and Comparisons eAnswers online. Waltham, MA: UpToDate Inc.; 2025. Accessed September 2025. Available <https://www.wolterskluwer.com/en/solutions/uptodate/enterprise/lexidrug-facts-and-comparisons>
4. Drugs@FDA: FDA approved drug products. Accessed September 2025. <https://www.accessdata.fda.gov/scripts/cder/daf/>.
5. US Food and Drug Administration. Purple Book: Database of Licensed Biological Products. US Food and Drug Administration. Updated April 27, 2023. Accessed September 2025. <https://purplebooksearch.fda.gov/>
6. Aimovig [package insert]. Thousand Oaks, CA: Amgen Inc.; 2025
7. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025
8. Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022
9. Vyepti [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; 2025
10. Zavzpret [package insert]. New York, NY: Pfizer Inc.; 2025
11. Ajovy [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2025
12. Ubrelvy [package insert]. North Chicago, IL: AbbVie Inc.; 2025
13. Nurtec [package insert]. New York, NY: Pfizer Inc.; 2025
14. Qulipta [package insert]. North Chicago, IL: AbbVie Inc.; 2025
15. Qaseem A, Cooney TG, Etzeandia-Ikobaltzeta I, et al. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. *Ann Intern Med.* 2025;178(3):426-433. doi:10.7326/ANNALS-24-01052
16. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. *Headache.* 2024;64(4):333-341. doi:10.1111/head.14692
17. Sun W, Cheng H, Xia B, et al. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis. *Clin J Pain.* 2023;39(10):560-569. Published 2023 Oct 1. doi:10.1097/AJP.0000000000001136
18. Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. *J Headache Pain.* 2023;24(1):56. Published 2023 May 19. doi:10.1186/s10194-023-01594-1
19. International Headache Society. Episodic Cluster Headache. Accessed September 17, 2025. <https://ichd-3.org/3-trigeminal-autonomic-cephalalgias/3-1-cluster-headache/3-1-1-episodic-cluster-headache/>
20. Malu OO, Bailey J, Hawks MK. Cluster Headache: Rapid Evidence Review. *Am Fam Physician.* 2022;105(1):24-32.
21. May, A. Cluster Headache: Treatment and Prognosis. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (September 17, 2025.)
22. Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. *Expert Opin Ther Targets.* 2020;24(2):91-100. doi:10.1080/14728222.2020.1724285
23. Cutrer FM (2023). Pathophysiology, clinical manifestations, and diagnosis of migraine in adults. In Swanson JW, Goddeau RP (Eds.), *UpToDate*. Available from: [Pathophysiology, clinical manifestations, and diagnosis of migraine in adults - UpToDate](#).
24. Garza I, Schwedt TJ (2023). Chronic migraine. In Swanson JW & Robertson CE (Eds.), *UpToDate*. Available from: [Chronic migraine - UpToDate](#).



**Revision History**

Date	Version	Revisions
11/7/2025	V1	Document approved by DSS